Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation

Abstract:
BioAlliance Pharma SA (Euronext Paris: BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation

Paris | Posted on November 13th, 2009

Oral chemotherapy is a great challenge and its success is expected to make a major breakthrough in cancer chemotherapy in the following years.

BioAlliance Pharma is developing an innovative proprietary nanoparticle technology offering new therapeutic solutions for oral administration in oncology. Using Sustained Release Nanoparticles (SRN) formulation, oral chemotherapy can maintain optimum drug plasma concentrations, providing prolonged exposure to cancer cells, then improving the efficacy and tolerance.

The data presented at the AAPS Meeting showed that the new oral formulation of irinotecan (IRN-SRN) entrapped into nanoparticles, allowing an oral delivery of IRN, significantly prolonged plasmatic half lives of IRN and SN-38, its active metabolite, compared to those observed after the intravenous administration of IRN, then increasing exposure to the active drug.

The IRN-SRN formulation tested in vivo in models of colorectal tumours was demonstrated to have similar efficacy on tumour growth inhibition and to be better tolerated than IRN administered IV.

"This oral nanoparticle innovation opens new ways to chemotherapy agents in cancer treatments," commented Dominique Costantini, President and CEO, BioAlliance Pharma.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

####

About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

About the American Association of Pharmaceutical Scientists (AAPS)

The purpose of AAPS is to serve its membership, the pharmaceutical sciences, the biomedical and biotechnological community, the health professions, and the interest of public health. This is accomplished by providing open forums for the exchange and dissemination of scientific knowledge; by fostering the education and career growth of members and recognizing individual achievement; by influencing the formation of public policy relevant to health and related issues of public concern; and, by promoting the pharmaceutical sciences as they relate to health issues of public concern. Through its Annual Meeting, its conferences, workshops and symposia, through its print and online publications and other on-line initiatives, AAPS continues to offer vital benefits to the pharmaceutical scientists who constitute its membership.

Recognizing that modern science is conducted in an integrated fashion comprising many disciplines, AAPS seeks to foster the integration of those sciences related to discovery, design, analysis, development, production, quality control, safety, clinical evaluation, regulation, distribution and utilization of drugs and drug delivery systems. Thus, AAPS should serve as the primary focus and forum for interest in these disciplines.

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
+33-1-4558-7601
President and CEO


Nicolas Fellmann
+33-1-4558-7100
CFO


ALIZE RP
Caroline Carmagnol
+33-6-6418-9959

Copyright © BioAlliance Pharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Physicists build reversible laser tractor beam October 20th, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

1980s aircraft helps quantum technology take flight October 20th, 2014

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Products

HZO Teams With Deutsche Telekom to Unveil the Waterproof Tolino Vision 2 eReader: The New HZO Protected eReader Ushers in a New Era of Waterproof Electronics, Providing a Seamless User Experience Without the Risk of Using Port Doors and Mechanical Seals October 10th, 2014

7th Nanotechnology Festival, Exhibition Kicks Off Work in Iran October 7th, 2014

Next-Gen Luxury RV From Global Caravan Technologies Will Offer MagicView Roof and Windshield Using SPD-SmartGlass Technology From Research Frontiers: Recreational Vehicle Manufacturer Global Caravan Technologies (GCT) Features 28 Square Feet of MagicView™ SPD-SmartGlass September 17th, 2014

Fonon at Cutting-Edge of 3D Military Printing: Live-Combat Scenarios Could See a Decisive Advantage with 3D Printing September 15th, 2014

Nanomedicine

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014

Announcements

Physicists build reversible laser tractor beam October 20th, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

1980s aircraft helps quantum technology take flight October 20th, 2014

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Events/Classes

Ucore's McKenzie to Deliver Presentation to Rare Earths Conference in Singapore as Highlight of Fall 2014 Marketplace Schedule October 19th, 2014

Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014

New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014

Nanotronics Imaging Releases nSPEC® 3D, Powerful Microscope That Captures 3D Images at Nanoscale, in Lightning Speed: Company Unveils Design at American Chemical Society 2014 International Elastomer Conference October 14th, 2014

Nanobiotechnology

Scientists Map Key Moment in Assembly of DNA-Splitting Molecular Machine: Crucial steps and surprising structures revealed in the genesis of the enzyme that divides the DNA double helix during cell replication October 15th, 2014

DNA nano-foundries cast custom-shaped metal nanoparticles: DNA's programmable assembly is leveraged to form precise 3D nanomaterials for disease detection, environmental testing, electronics and beyond October 10th, 2014

Charged graphene gives DNA a stage to perform molecular gymnastics October 9th, 2014

Nanoparticles get a magnetic handle: New method produces particles that can glow with color-coded light and be manipulated with magnets October 9th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE